Kliničke studije za Рак дојке u državi Alabama
32 studija za Рак дојке traži učesnike na lokacijama u državi Alabama.
Gradovi u državi Alabama
Zvanični tekst studije (na engleskom)
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
- O'Neal Comprehensive Cancer Center/The University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07069595An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- University of Alabama At Birmingham Hospital, Birmingham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07222267A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
- Clearview Cancer Institute - Huntsville, Huntsville
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 12. 11. 2026. · NCT07541079Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- University of Alabama Birmingham, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT05693766INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
- University of Alabama at Birmingham, Birmingham
Тражи се учесникНаводи исплату за учеснике
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07671937A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 4. 11. 2026. · NCT07287098A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06760819A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Southern Cancer Center (SCC) ( Site 8000), Daphne
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07060807A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Clearview Cancer Institute - Huntsville, Huntsville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT07100106Post-market Evaluation of LumiSystem: Intraoperative Margin Performance and Clinical Utility (IMPACT) Registry
- University of South Alabama Health, Mobile
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07616856Post-market Safety Study of LUMISIGHT
- University of South Alabama Health, Mobile
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT07572162Mind-Body Group Interventions for Psychological Distress in Young Breast Cancer Survivors
- UAB School of Health Professions, Birmingham
- University of Alabama at Birmingham O'Neal Cancer Center, Birmingham
Тражи се учесник
Узраст од 18 до 50 · Жене · Ажурирано 16. 10. 2026. · NCT07501637Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Alabama Birmingham, Birmingham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 10. 2026. · NCT06293898A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Alabama Oncology, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 1. 10. 2026. · NCT06369285PRE-ISPY Phase I/II Oncology Platform Program
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 30. 9. 2026. · NCT05868226Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 2
Узраст 60 и старији · Жене · Ажурирано 30. 9. 2026. · NCT06105684Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
- The Kirklin Clinic, Birmingham
Тражи се учесник
Узраст од 18 до 90 · Жене · Ажурирано 25. 9. 2026. · NCT06294574A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Daphne
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT06103864A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 23. 9. 2026. · NCT06618287Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- University of Alabama at Birmingham, Birmingham
Тражи се учесникЗдраве особе су добродошле
Узраст од 30 до 74 · Жене · Ажурирано 21. 9. 2026. · NCT02620852Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Birmingham Hematology Associates, Birmingham
Тражи се учесникОпсервациона студија
Узраст од 18 до 99 · Оба пола · Ажурирано 3. 9. 2026. · NCT07211178TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- University of Alabama, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 26. 8. 2026. · NCT06533826Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- Southern Cancer Center, Mobile
Тражи се учесникФаза 3
Узраст од 18 до 100 · Оба пола · Ажурирано 6. 8. 2026. · NCT05232916Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
- University of Alabama, Birmingham, Birmingham
Тражи се учесникЗдраве особе су добродошле
Узраст од 45 до 74 · Жене · Ажурирано 31. 7. 2026. · NCT05625659Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Uni of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 1
Узраст од 18 до 100 · Оба пола · Ажурирано 29. 7. 2026. · NCT06562192Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
- The University of Alabama, Birmingham
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 15. 5. 2026. · NCT06855654I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 6. 5. 2026. · NCT01042379Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- University of Alabama at Birmingham, Birmingham
- University of South Alabama, Mobile
Тражи се учесник
Узраст 18 и старији · Оба пола · Ажурирано 30. 4. 2026. · NCT05297734De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- University of South Alabama Mitchell Cancer Institute, Mobile
Тражи се учесникФаза 3
Узраст од 50 до 70 · Оба пола · Ажурирано 23. 4. 2026. · NCT04852887A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 25. 2. 2026. · NCT06099769Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
- The Kirklin Clinic, Birmingham
Тражи се учесникРана фаза 1
Узраст 18 и старији · Жене · Ажурирано 26. 1. 2026. · NCT03321045SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.